奥沙利铂联合替吉奥治疗晚期结直肠癌的临床效果(1)
[摘要] 目的 探讨采取奥沙利铂联合替吉奥治疗晚期结直肠癌的临床疗效。 方法 选取2016年5月～2017年5月期间我院接收的68例晚期结直肠癌患者，将入选者随机分为对照组(n=34，采取奥沙利铂+卡培他滨治疗)与观察组(n=34，采取奥沙利铂联合替吉奥治疗)，两组共治疗2个疗程，观察疗效及1年生存率、不良反应发生率等。 结果 治疗后，观察组患者的客观缓解率明显高于对照组(P<0.05);观察组患者1年生存率为70.59%(24/34)，对照组为52.94%(18/34)，两组比较差异显著(P<0.05)。观察组中位疾病进展时间为(8.22±0.52)个月，对照组为(8.11±0.43)個月(P>0.05);观察组血小板减少、呕心呕吐、贫血、中性粒细胞减少率较对照组明显要低(P<0.05)。 结论 奥沙利铂联合替吉奥相比于奥沙利铂联合卡培他滨方案，对晚期结直肠癌的临床疗效更为显著，安全性更高，值得推广。
[关键词] 奥沙利铂;结直肠癌;替吉奥;卡培他滨
[中图分类号] R735.34 [文献标识码] B [文章编号] 1673-9701(2019)17-0102-03
[Abstract] Objective To investigate the clinical efficacy of oxaliplatin combined with tegafur in the treatment of advanced colorectal cancer. Methods 68 patients with advanced rectal cancer in our hospital from May 2016 to May 2017 were enrolled. The patients were randomly divided into the control group(n=34， treated with oxaliplatin+capecitabine) and the observation group(n=34， treated with oxaliplatin combined with tegafur). The two groups were treated for 2 courses. The efficacy， 1-year survival rate， adverse reaction rate and so on were observed. Results After treatment， the objective response rate of the observation group was significantly higher than that of the control group(P<0.05). The 1-year survival rate of the observation group was 70.59%(24/34)， and that of the control group was 52.94%(18/34). The difference between the two groups was significant(P<0.05). The median disease progression time was(8.22±0.52) months in the observation group and(8.11±0.43) months in the control group(P>0.05). The incidences of thrombocytopenia， vomiting and vomiting， anaemia and neutropenia in the observation group were significantly higher than those in the control group(P<0.05). Conclusion Oxaliplatin combined with tegafur is more effective than oxaliplatin combined with capecitabine in the treatment of advanced colorectal cancer， and is more safe and worth promoting.
[Key words] Oxaliplatin; Colorectal cancer; Tegafur; Capecitabine
结直肠癌在临床上发病率较高，由于其起病较为隐匿，多数患者在发现时已为中晚期，预后往往较差。晚期结直肠癌临床多采用奥沙利铂联合卡培他滨治疗，虽然有一定的疗效，但毒副作用较多，严重影响患者的生活质量和健康。替吉奥是一种复方口服胶囊制剂，已有研究指出[1]，其毒副反应较轻，且疗效较好。本研究通过对2016年5月～2017年5月期间我院接收的晚期结直肠癌患者临床资料进行回顾性分析，探讨采取奥沙利铂联合替吉奥治疗晚期结直肠癌的临床疗效，现报道如下。
1资料与方法
1.1一般资料
选取2016年5月～2017年5月我院接收的68例晚期结直肠癌患者，纳入标准：(1)患者经细胞学检查确诊，并符合《外科学》中关于结直肠癌的诊断标准;(2)预计生存期不少于4个月，经化疗后仍出现病灶转移;(3)经医院伦理委员会批准，患者均知情同意。排除标准：肝、脑、肾功能不全者;中枢神经转移病灶者;骨髓储备功能异常者。将入选患者随机分为对照组(n=34，采取奥沙利铂+卡培他滨治疗)与观察组(n=34，采取奥沙利铂联合替吉奥治疗)。观察组中，女12例，男22例，年龄31～76岁，平均(55.62±2.11)岁;平均病程(3.41±0.65)年，临床分期：Ⅲ期18例，Ⅳ期16例;转移部位：肺13例，淋巴结16例，其他器官5例;对照组中，女11例，男23例，年龄32～75岁，平均(55.81±1.94)岁，平均病程(3.21±0.54)年，临床分期：Ⅲ期19例，Ⅳ期15例;转移部位：肺14例，淋巴结15例，其他器官5例。在年龄、性别等资料上，两组晚期结直肠癌患者比较无明显差异(P>0.05)，具有可比性。, http://www.100md.com(项艳 刘央央 王慧玉)
[关键词] 奥沙利铂;结直肠癌;替吉奥;卡培他滨
[中图分类号] R735.34 [文献标识码] B [文章编号] 1673-9701(2019)17-0102-03
[Abstract] Objective To investigate the clinical efficacy of oxaliplatin combined with tegafur in the treatment of advanced colorectal cancer. Methods 68 patients with advanced rectal cancer in our hospital from May 2016 to May 2017 were enrolled. The patients were randomly divided into the control group(n=34， treated with oxaliplatin+capecitabine) and the observation group(n=34， treated with oxaliplatin combined with tegafur). The two groups were treated for 2 courses. The efficacy， 1-year survival rate， adverse reaction rate and so on were observed. Results After treatment， the objective response rate of the observation group was significantly higher than that of the control group(P<0.05). The 1-year survival rate of the observation group was 70.59%(24/34)， and that of the control group was 52.94%(18/34). The difference between the two groups was significant(P<0.05). The median disease progression time was(8.22±0.52) months in the observation group and(8.11±0.43) months in the control group(P>0.05). The incidences of thrombocytopenia， vomiting and vomiting， anaemia and neutropenia in the observation group were significantly higher than those in the control group(P<0.05). Conclusion Oxaliplatin combined with tegafur is more effective than oxaliplatin combined with capecitabine in the treatment of advanced colorectal cancer， and is more safe and worth promoting.
[Key words] Oxaliplatin; Colorectal cancer; Tegafur; Capecitabine
结直肠癌在临床上发病率较高，由于其起病较为隐匿，多数患者在发现时已为中晚期，预后往往较差。晚期结直肠癌临床多采用奥沙利铂联合卡培他滨治疗，虽然有一定的疗效，但毒副作用较多，严重影响患者的生活质量和健康。替吉奥是一种复方口服胶囊制剂，已有研究指出[1]，其毒副反应较轻，且疗效较好。本研究通过对2016年5月～2017年5月期间我院接收的晚期结直肠癌患者临床资料进行回顾性分析，探讨采取奥沙利铂联合替吉奥治疗晚期结直肠癌的临床疗效，现报道如下。
1资料与方法
1.1一般资料
选取2016年5月～2017年5月我院接收的68例晚期结直肠癌患者，纳入标准：(1)患者经细胞学检查确诊，并符合《外科学》中关于结直肠癌的诊断标准;(2)预计生存期不少于4个月，经化疗后仍出现病灶转移;(3)经医院伦理委员会批准，患者均知情同意。排除标准：肝、脑、肾功能不全者;中枢神经转移病灶者;骨髓储备功能异常者。将入选患者随机分为对照组(n=34，采取奥沙利铂+卡培他滨治疗)与观察组(n=34，采取奥沙利铂联合替吉奥治疗)。观察组中，女12例，男22例，年龄31～76岁，平均(55.62±2.11)岁;平均病程(3.41±0.65)年，临床分期：Ⅲ期18例，Ⅳ期16例;转移部位：肺13例，淋巴结16例，其他器官5例;对照组中，女11例，男23例，年龄32～75岁，平均(55.81±1.94)岁，平均病程(3.21±0.54)年，临床分期：Ⅲ期19例，Ⅳ期15例;转移部位：肺14例，淋巴结15例，其他器官5例。在年龄、性别等资料上，两组晚期结直肠癌患者比较无明显差异(P>0.05)，具有可比性。, http://www.100md.com(项艳 刘央央 王慧玉)